- Home
- ENLV vs VCIG Comparison
ENLV vs VCIG Comparison
Compare ENLV & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLV
- VCIG
- Stock Information
- Founded
- ENLV 2005
- VCIG 2013
- Country
- ENLV Israel
- VCIG Malaysia
- Employees
- ENLV N/A
- VCIG N/A
- Industry
- ENLV Biotechnology: Pharmaceutical Preparations
- VCIG Diversified Commercial Services
- Sector
- ENLV Health Care
- VCIG Consumer Discretionary
- Exchange
- ENLV Nasdaq
- VCIG Nasdaq
- Market Cap
- ENLV 20.7M
- VCIG 26.3M
- IPO Year
- ENLV 1995
- VCIG 2023
- Fundamental
- Price
- ENLV $1.01
- VCIG $0.32
- Analyst Decision
- ENLV Strong Buy
- VCIG
- Analyst Count
- ENLV 2
- VCIG 0
- Target Price
- ENLV $10.00
- VCIG N/A
- AVG Volume (30 Days)
- ENLV 146.1K
- VCIG 2.7M
- Earning Date
- ENLV 04-11-2025
- VCIG 04-08-2025
- Dividend Yield
- ENLV N/A
- VCIG 155.11%
- EPS Growth
- ENLV N/A
- VCIG N/A
- EPS
- ENLV N/A
- VCIG 7.82
- Revenue
- ENLV N/A
- VCIG $23,548,256.00
- Revenue This Year
- ENLV N/A
- VCIG N/A
- Revenue Next Year
- ENLV N/A
- VCIG N/A
- P/E Ratio
- ENLV N/A
- VCIG $0.04
- Revenue Growth
- ENLV N/A
- VCIG 89.38
- 52 Week Low
- ENLV $0.81
- VCIG $0.29
- 52 Week High
- ENLV $4.59
- VCIG $68.60
- Technical
- Relative Strength Index (RSI)
- ENLV 44.89
- VCIG 26.92
- Support Level
- ENLV $0.92
- VCIG $0.29
- Resistance Level
- ENLV $1.13
- VCIG $0.50
- Average True Range (ATR)
- ENLV 0.10
- VCIG 0.12
- MACD
- ENLV -0.01
- VCIG -0.02
- Stochastic Oscillator
- ENLV 24.32
- VCIG 4.31
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development solution consultancy. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology Consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment which focuses on listing solutions, investor relations, and boardroom strategies consultancy. It has established a diverse local and international clientele, providing them with its services in both local and cross-border listings. Its role begins with pre-listing diagnosis and planning to the finalization of the entire listing process.